- ►annals.org HD Nelson, LH Huffman, R Fu, EL Harris - Annals of internal medicine, 2005 - Am Coll Physicians Background: Clinically significant mutations of BRCA1 and BRCA2 genes are
associated with increased susceptibility for breast and ovarian cancer. Although
these mutations are uncommon, public interest in testing for them is growing. Cited by 93 - Related articles - BL Direct - All 11 versions
S Wainberg, J Husted - Cancer Epidemiology Biomarkers & Prevention, 2004 - AACR Objective: Women who are carriers of BRCA gene mutations have an elevated
lifetime risk of developing breast or ovarian cancer. Although a number of
risk-reducing options are currently available to mutation carriers, ... Cited by 65 - Related articles - All 4 versions
CP Kaplan, JS Haas, EJ Pérez-Stable, G Des … - Preventive Medicine, 2005 - Elsevier Of 1647 eligible physicians, 822 responded. Eighty-six percent reported
initiating counseling, 45% referred a patient for genetic evaluation, 31%
prescribed raloxifene, and 11% prescribed tamoxifen for breast cancer ... Cited by 10 - Related articles - All 3 versions
- ►oxfordjournals.org G Pichert, B Bolliger, K Buser, O Pagani - Annals of Oncology, 2003 - Eur Soc Med Oncology Recent developments in our ability to predict breast cancer risk necessitates
primary care physicians learn to evaluate breast cancer risk and its importance
in shaping decisions concerning surveillance and risk reduction measures. ... Cited by 37 - Related articles - BL Direct - All 7 versions
SA Narod, K Offit - J Clin Oncol, 2005 - jco.ascopubs.org It has been 10 years since the BRCA1 gene was first identified. During this
decade, genetic testing for breast cancer susceptibility has been incorporated
into the practice of oncology. In this process, the identification of ... Cited by 83 - Related articles - All 10 versions
- ►prsjournal.com KA Phillips, MA Jenkins, GJ Lindeman, SA … - Clinical genetics, 2006 - prsjournal.com This study prospectively evaluated the utilization of cancer risk management
strategies in a multi-institutional cohort of BRCA1 and BRCA2 mutation carriers
using a self-report questionnaire. Of 142 unaffected female mutation ... Cited by 19 - Related articles - Cached - All 5 versions
[CITATION] Last literature review version 17.1: Thu Jan 01 00: 00: 00 GMT 2009| This topic last updated …
- ►bmj.com H Hampel, K Sweet, JA Westman, K Offit, C … - British Medical Journal, 2004 - jmg.bmj.com Results: Based on family history, a set of criteria was developed to identify
patients at risk for a hereditary cancer susceptibility syndrome, patients with
moderate risk who might benefit from increased cancer surveillance, and ... Cited by 76 - Related articles - BL Direct - All 7 versions
M Palma, E Ristori, E Ricevuto, G Giannini, A … - Critical Reviews in Oncology and Hematology, 2006 - Elsevier Approximately 5–10% of breast carcinomas and 10% of ovarian carcinomas are
ascribable to a genetic susceptibility. Of these, about 40% are related to
genetic mutations in the genes BRCA1 and BRCA2. Despite the increasing ... Cited by 16 - Related articles - All 12 versions
